Derek Raghavan
Impact in
Papers in
-
- Prostate Cancer Treatment and Research 52
- Prostate Cancer Diagnosis and Treatment 23
- Lung Cancer Treatments and Mutations 15
- Surgery 139
- Bladder and Urothelial Cancer Treatments 83
- Testicular diseases and treatments 45
- Urinary and Genital Oncology Studies 33
- Co-authors
- Catherine M. Tangen (7 shared papers)Maha Hussain (6 shared papers)E. David Crawford (5 shared papers)Michael F. Sarosdy (2 shared papers)Eric Jay Small (3 shared papers)John P. Stein (6 shared papers)Howard I. Scher (3 shared papers)Donald G. Skinner (7 shared papers)
- Journals
- Journal of Clinical Oncology (39 papers)Cancer (15 papers)European Journal of Cancer (11 papers)The Journal of Urology (10 papers)Cancer Chemotherapy and Pharmacology (8 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Derek Raghavan
299 papers receiving 22.4k citations
Derek Raghavan's Hit Papers
Peers
Comparison fields: 5 of 159
- Oncology 5.8k
- Surgery 9.2k
- Pulmonary and Respiratory Medicine 6.6k
- Urology 1.1k
- Cancer Research 2.7k
Countries citing papers authored by Derek Raghavan
This map shows the geographic impact of Derek Raghavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek Raghavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek Raghavan more than expected).
Fields of papers citing papers by Derek Raghavan
This network shows the impact of papers produced by Derek Raghavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek Raghavan. The network helps show where Derek Raghavan may publish in the future.
Co-authors
The 25 scholars most cited alongside Derek Raghavan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 310 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer Hit paper breakdown → | 2004 | 3079 |
| 2 | Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients Hit paper breakdown → | 2001 | 2862 |
| 3 | Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer Hit paper breakdown → | 2003 | 2119 |
| 4 | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2008 | 1898 |
| 5 | A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Hit paper breakdown → | 1992 | 808 |
| 6 | American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options Hit paper breakdown → | 2015 | 775 |
| 7 | Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received Hit paper breakdown → | 2016 | 548 |
| 8 | Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Hit paper breakdown → | 2009 | 530 |
| 9 | American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology Hit paper breakdown → | 2012 | 513 |
| 10 | Intermittent versus Continuous Androgen Deprivation in Prostate Cancer Hit paper breakdown → | 2013 | 446 |
| 11 | Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Hit paper breakdown → | 1997 | 415 |
| 12 | 2006 | 402 | |
| 13 | Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 Hit paper breakdown → | 2012 | 364 |
| 14 | 1990 | 344 | |
| 15 | 1997 | 292 | |
| 16 | 2006 | 241 | |
| 17 | 2008 | 234 | |
| 18 | 2000 | 198 | |
| 19 | 2014 | 191 | |
| 20 | 2011 | 186 |
About Derek Raghavan
Derek Raghavan is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Cancer Research and Biotechnology, having authored 310 papers that have together received 23.4k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (83 papers), Prostate Cancer Treatment and Research (52 papers), Testicular diseases and treatments (45 papers), Urinary and Genital Oncology Studies (33 papers), Prostate Cancer Diagnosis and Treatment (23 papers), Cancer Treatment and Pharmacology (19 papers), Lung Cancer Research Studies (15 papers) and Lung Cancer Treatments and Mutations (15 papers). The work is most often cited by research in Oncology (5.8k citations), Surgery (9.2k citations), Pulmonary and Respiratory Medicine (6.6k citations), Urology (1.1k citations) and Cancer Research (2.7k citations). Derek Raghavan has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Catherine M. Tangen, Maha Hussain, E. David Crawford, Michael F. Sarosdy, Eric Jay Small, John P. Stein, Howard I. Scher, Donald G. Skinner, Kenneth J. Pienta and Johann Sebastian De Bono. Their work appears in journals such as Journal of Clinical Oncology, Cancer, European Journal of Cancer, The Journal of Urology and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.